David Alan

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 142 citations · Full text

The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction

Petr Ošťádal, David Alan, Petr Hájek et al. · 2003 · 33 citations

Inflammation, Thrombosis, Cardiovascular Disease +9

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Petr Ošťádal, David Alan, Jiří Vejvoda et al. · Trials · 2010 · 29 citations · Full text

Alterations in serum selenium levels and their relation to troponin I in acute myocardial infarction

Barbara Kutil, Petr Ošťádal, Jiří Vejvoda et al. · Molecular and Cellular Biochemistry · 2010 · 25 citations

Allergy, Selenium Deficiency, Cardiovascular Disease +2

Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]

Petr Ošťádal, David Alan, Petr Hájek et al. · Current Controlled Trials in Cardiovascular Medicine · 2005 · 22 citations · Full text